Enveric Biosciences, Inc. ENVB
1.50
(0.05)
(3.23%)
as of 25 Sep
- Market cap
- $6.9M
- P/E
- 0.0×
Follow ENVB
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
— | — | — | — | — | — | 18.35 | 0.00 | 12,862,075.64 | 31,776,179.26 |
P/FCF ratio |
— | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
P/Operating CF |
— | — | — | — | — | — | 886.17 | 0.00 | (664,062,733.74) | 3,912,019,976.16 |
P/B ratio |
— | — | — | — | — | — | 0.00 | 0.00 | 32,144,241.44 | 98,504,220.80 |
Price to Tangible BV |
— | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Sales |
— | — | — | — | — | — | 18.47 | 0.12 | 12,862,075.69 | 31,776,179.74 |
EV/EBITDA |
— | — | — | — | — | — | 25.76 | 1.06 | 0.00 | 0.00 |
EV/Operating CF |
— | — | — | — | — | — | (1,138.03) | (1.98) | (228,041,392.04) | (424,766,672.43) |
EV/FCF |
— | — | — | — | — | — | (258.97) | (1.09) | (159,593,454.87) | (420,244,075.32) |
Quick Ratio |
5.09 | 1.50 | 0.98 | 4.44 | 6.34 | 2.32 | 3.35 | 0.63 | 0.45 | 0.74 |
Current Ratio |
5.38 | 1.84 | 1.53 | 4.61 | 6.48 | 3.35 | 0.06 | 0.69 | 0.48 | 0.79 |
Net Debt/EBITDA |
0.55 | 0.24 | 0.14 | 0.90 | 0.68 | 0.30 | (0.31) | 0.80 | (0.30) | (4.29) |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.33% | 0.66% | 0.00% | 680.42% | 17.57% | 13.76% | 47.15% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | (0.41) | 0.48 | 0.37 | 1.60 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.68 | 1.05 | 1.06 | 1.36 |
Operating CF/Net income |
0.67 | 0.81 | 0.81 | 0.91 | 0.23 | 0.57 | 0.27 | 0.13 | 0.25 | 0.97 |
Capex/Depreciation |
0.00 | 0.00 | 0.03 | (0.07) | 0.00 | 0.00 | (1.23) | 0.00 | 0.00 | (0.02) |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| (420.48%) | (539.57%) | (209.99%) | (101.68%) | (381.31%) | (875.21%) | (53.93%) | (129.02%) | (71.78%) | (46.66%) | |
| (296.67%) | (259.40%) | (146.39%) | (81.26%) | (317.87%) | (326.45%) | (16.21%) | (47.61%) | (24.35%) | (10.43%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | (787.91%) | (191.11%) | 0.00% | (30.60%) | (31.31%) | (11.63%) |
Return on Tangible Assets |
(290.40%) | (617.46%) | (1,000.28%) | (124.39%) | (320.24%) | (429.61%) | 139.47% | 426.39% | 71.44% | 109.31% |
Average Days of Receivables |
— | — | — | — | — | — | 58.38 | 66.82 | 66.39 | 81.39 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 5.75% | 25.11% | 38.09% | 25.90% |
Intangible Assets out of Total Assets |
0.00 | 0.01 | 0.05 | 0.02 | 0.32 | 0.44 | 159.14 | 0.66 | 0.60 | 0.65 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 1.56% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
— | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
Graham Number |
— | — | — | — | — | — | 23,967.29 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
— | — | — | — | — | — | (0.69%) | (18.39%) | (0.39%) | 0.00% |
Free Cash Flow Yield |
— | — | — | — | — | — | (0.39%) | 0.00% | 0.00% | 0.00% |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 66,524.50 | 0.00 | 3.24 | 2.77 |
Operating CF per Share |
(24.32) | (184.39) | (1,174.53) | (2,143.34) | (4,406.81) | (6,481.33) | (1,079.83) | 0.00 | (0.18) | (0.21) |
Capex per Share |
0.00 | 0.00 | 0.98 | (73.02) | (72.96) | 0.00 | (140.50) | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
(24.32) | (184.39) | (1,173.56) | (2,216.36) | (4,479.77) | (6,481.33) | (1,220.33) | 0.00 | (0.18) | (0.21) |
Cash per Share |
13.98 | 53.48 | 190.67 | 2,215.49 | 6,675.38 | 2,630.83 | 72.83 | 0.00 | 0.33 | 0.11 |
Shareholders Equity per Share |
12.48 | 38.01 | 163.03 | 1,833.99 | 8,579.19 | 5,692.67 | (3,019.33) | 0.00 | 1.30 | 0.89 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
12.48 | 38.01 | 163.03 | 1,833.99 | 8,579.19 | 5,692.67 | (3,019.33) | 0.00 | 1.30 | 0.89 |
Free Cash Flow |
(8.14) | (7.73) | (14.08) | (17.73) | (11.65) | (3.89) | (0.73) | (2.56) | (2.75) | (2.73) |
Working Capital |
4.02 | 1.24 | 1.24 | 14.44 | 15.00 | 1.60 | (1.81) | (4.63) | (15.72) | (2.64) |
Capital Expenditures |
— | — | 0.01 | (0.58) | (0.19) | (0.04) | (0.08) | 0.01 | 0.00 | (0.03) |
Net Current Asset Value |
4.02 | 1.24 | 1.24 | 13.55 | 13.32 | 1.60 | (1.81) | (8.82) | (18.10) | (17.78) |
EV/EBIT |
— | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
— | — | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (6.04%) | (45.31%) | (22.97%) | (7.69%) |
Price to Operating Income |
— | — | — | — | — | — | 25.64 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
1.26 | 1.10 | 0.80 | 11.64 | 133.70 | 0.00 | 0.82 | 202.75 | 33.87 | 13.58 |
Cash ROIC |
(93.74%) | (209.50%) | (344.03%) | (54.91%) | (29.50%) | (77.87%) | 71.14% | (15.14%) | (9.00%) | (8.85%) |
Accounts Receivable Turnover |
— | — | — | — | — | — | 5.60 | 5.15 | 5.75 | 5.59 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.76 | 1.00 | 0.13 | 11.48 | 7.01 | 7.34 | 7.56 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 388.57 | 365.96 | 2,056.86 | 13.30 | 46.98 | 50.67 | 64.10 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
— | — | — | — | — | — | 7.13 | 8.35 | 8.45 | 6.47 |
Average Payables |
0.55 | 0.87 | 0.84 | 0.57 | 0.68 | 0.92 | 2.77 | 4.85 | 5.23 | 3.86 |
Average Assets |
4.09 | 3.69 | 11.93 | 23.14 | 15.41 | 2.10 | 14.87 | 40.92 | 45.85 | 26.67 |
Average Common Equity |
2.89 | 1.77 | 8.31 | 18.49 | 12.84 | 0.78 | 4.47 | 15.10 | 15.55 | 5.96 |
Columns are period end dates